Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Serotonin 2a (5-HT2a) receptor | Starlite/ChEMBL | References |
Rattus norvegicus | Dopamine D2 receptor | Starlite/ChEMBL | References |
Rattus norvegicus | Dopamine D1 receptor | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma japonicum | 5-hydroxytryptamine receptor 1, putative | Get druggable targets OG5_132667 | All targets in OG5_132667 |
Schistosoma japonicum | 5-hydroxytryptamine receptor, putative | Get druggable targets OG5_132667 | All targets in OG5_132667 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0131 | 0.0288 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1937 | 1 | 1 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0862 | 0.4219 | 0.4219 |
Brugia malayi | Latrophilin receptor protein 2 | 0.0613 | 0.2881 | 0.2881 |
Schistosoma mansoni | hypothetical protein | 0.0613 | 0.2881 | 0.3707 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.1937 | 1 | 1 |
Brugia malayi | TAR-binding protein | 0.1431 | 0.7282 | 0.7282 |
Schistosoma mansoni | tar DNA-binding protein | 0.1431 | 0.7282 | 1 |
Schistosoma mansoni | hypothetical protein | 0.1324 | 0.6705 | 0.9175 |
Loa Loa (eye worm) | RNA binding protein | 0.1431 | 0.7282 | 0.7282 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.1324 | 0.6705 | 0.6705 |
Toxoplasma gondii | isocitrate dehydrogenase | 0.0131 | 0.0288 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1252 | 0.6317 | 0.6317 |
Trypanosoma brucei | isocitrate dehydrogenase, putative | 0.0131 | 0.0288 | 1 |
Brugia malayi | isocitrate dehydrogenase | 0.0131 | 0.0288 | 0.0288 |
Schistosoma mansoni | hypothetical protein | 0.0613 | 0.2881 | 0.3707 |
Brugia malayi | RNA recognition motif domain containing protein | 0.1431 | 0.7282 | 0.7282 |
Toxoplasma gondii | isocitrate dehydrogenase | 0.0131 | 0.0288 | 1 |
Echinococcus granulosus | neuropeptide receptor A26 | 0.0468 | 0.2105 | 0.2598 |
Echinococcus granulosus | tar DNA binding protein | 0.1431 | 0.7282 | 1 |
Echinococcus granulosus | cadherin EGF LAG seven pass G type receptor | 0.0613 | 0.2881 | 0.3707 |
Brugia malayi | calcium-independent alpha-latrotoxin receptor 2, putative | 0.0613 | 0.2881 | 0.2881 |
Schistosoma mansoni | tar DNA-binding protein | 0.1431 | 0.7282 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.1431 | 0.7282 | 1 |
Echinococcus granulosus | GPCR family 2 | 0.0613 | 0.2881 | 0.3707 |
Echinococcus multilocularis | GPCR, family 2 | 0.0613 | 0.2881 | 0.3707 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0862 | 0.4219 | 0.4219 |
Echinococcus granulosus | diuretic hormone 44 receptor GPRdih2 | 0.0613 | 0.2881 | 0.3707 |
Mycobacterium tuberculosis | Probable isocitrate dehydrogenase [NADP] Icd1 (oxalosuccinate decarboxylase) (IDH) (NADP+-specific ICDH) (IDP) | 0.0131 | 0.0288 | 0.5 |
Leishmania major | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0131 | 0.0288 | 1 |
Brugia malayi | RNA binding protein | 0.1431 | 0.7282 | 0.7282 |
Plasmodium falciparum | isocitrate dehydrogenase [NADP], mitochondrial | 0.0131 | 0.0288 | 1 |
Echinococcus granulosus | neuropeptide s receptor | 0.0468 | 0.2105 | 0.2598 |
Brugia malayi | MH2 domain containing protein | 0.0862 | 0.4219 | 0.4219 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.1431 | 0.7282 | 0.7282 |
Echinococcus multilocularis | tar DNA binding protein | 0.1431 | 0.7282 | 1 |
Echinococcus multilocularis | cadherin EGF LAG seven pass G type receptor | 0.0613 | 0.2881 | 0.3707 |
Trypanosoma cruzi | isocitrate dehydrogenase, putative | 0.0131 | 0.0288 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.1431 | 0.7282 | 1 |
Echinococcus multilocularis | neuropeptide receptor A26 | 0.0468 | 0.2105 | 0.2598 |
Loa Loa (eye worm) | hypothetical protein | 0.1324 | 0.6705 | 0.6705 |
Plasmodium vivax | isocitrate dehydrogenase [NADP], mitochondrial, putative | 0.0131 | 0.0288 | 1 |
Loa Loa (eye worm) | isocitrate dehydrogenase | 0.0131 | 0.0288 | 0.0288 |
Onchocerca volvulus | 0.1252 | 0.6317 | 0.5 | |
Schistosoma mansoni | hypothetical protein | 0.0613 | 0.2881 | 0.3707 |
Loa Loa (eye worm) | TAR-binding protein | 0.1431 | 0.7282 | 0.7282 |
Loa Loa (eye worm) | hypothetical protein | 0.0613 | 0.2881 | 0.2881 |
Schistosoma mansoni | tar DNA-binding protein | 0.1431 | 0.7282 | 1 |
Echinococcus multilocularis | neuropeptide s receptor | 0.0468 | 0.2105 | 0.2598 |
Trypanosoma brucei | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0131 | 0.0288 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0613 | 0.2881 | 0.3707 |
Brugia malayi | hypothetical protein | 0.1252 | 0.6317 | 0.6317 |
Echinococcus multilocularis | diuretic hormone 44 receptor GPRdih2 | 0.0613 | 0.2881 | 0.3707 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.1937 | 1 | 1 |
Brugia malayi | Isocitrate dehydrogenase | 0.0131 | 0.0288 | 0.0288 |
Loa Loa (eye worm) | latrophilin receptor protein 2 | 0.0613 | 0.2881 | 0.2881 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | = 1.98 mg kg-1 | In vivo Antipsychotic activity was quantified by inhibition of apomorphine-induced climbing(CL 95%) by mice | ChEMBL. | 10425088 |
ED50 (functional) | > 4 mg kg-1 | In vivo Antipsychotic activity was quantified by induction of catalepsy in mice | ChEMBL. | 10425088 |
Ki (binding) | = -7.95 | In vitro ability to displace [3H]-ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane. | ChEMBL. | 10425088 |
Ki (binding) | = -6.76 | In vitro ability to displace [3H]-spiperone binding from dopamine receptor D2 in rat striatal membrane. | ChEMBL. | 10425088 |
Ki (binding) | = -6.25 | In vitro ability to displace [3H]-SCH-23,390 binding from Dopamine 1 (D1) receptor in rat striatal membrane. | ChEMBL. | 10425088 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.